These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 11735804)

  • 1. Clinicopathologic reports, case reports, and small case series: 0.01% becaplermin gel for the treatment of a chronic orbital ulcer after exenteration.
    Yassur I; Hirschbein MJ; Karesh JW
    Arch Ophthalmol; 2001 Dec; 119(12):1858-9. PubMed ID: 11735804
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
    Wieman TJ; Smiell JM; Su Y
    Diabetes Care; 1998 May; 21(5):822-7. PubMed ID: 9589248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late-onset occult cerebrospinal fluid leakage after orbital exenteration.
    Yuen HK; Cheng AC; Auyeung KC
    Ophthalmic Plast Reconstr Surg; 2008; 24(3):238-40. PubMed ID: 18520849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group.
    Wieman TJ
    Am J Surg; 1998 Aug; 176(2A Suppl):74S-79S. PubMed ID: 9777976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of stingray injury with topical becaplermin gel.
    Baldinger PJ
    J Am Podiatr Med Assoc; 1999 Oct; 89(10):531-3. PubMed ID: 10546426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study.
    Rees RS; Robson MC; Smiell JM; Perry BH
    Wound Repair Regen; 1999; 7(3):141-7. PubMed ID: 10417749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical safety of becaplermin (rhPDGF-BB) gel. Becaplermin Studies Group.
    Smiell JM
    Am J Surg; 1998 Aug; 176(2A Suppl):68S-73S. PubMed ID: 9777975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies.
    Smiell JM; Wieman TJ; Steed DL; Perry BH; Sampson AR; Schwab BH
    Wound Repair Regen; 1999; 7(5):335-46. PubMed ID: 10564562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of chronic ulcers in the lower extremities with topical becaplermin gel .01%: a multicenter open-label study.
    Guzman-Gardearzabal E; Leyva-Bohorquez G; Salas-Colín S; Paz-Janeiro JL; Alvarado-Ruiz R; García-Salazar R
    Adv Ther; 2000; 17(4):184-9. PubMed ID: 11185057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addendum: Commentary on becaplermin gel (Regranex) for hemangiomas.
    Frieden IJ
    Pediatr Dermatol; 2008; 25(6):590. PubMed ID: 19067861
    [No Abstract]   [Full Text] [Related]  

  • 11. Platelet-derived growth factor for diabetic ulcers.
    Med Lett Drugs Ther; 1998 Jul; 40(1031):73-4. PubMed ID: 9698702
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of Regranex gel for diabetic foot ulcers.
    Piascik P
    J Am Pharm Assoc (Wash); 1998; 38(5):628-30. PubMed ID: 9782698
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful treatment of chronic wound in Klippel-Trenaunay syndrome with recombinant human platelet-derived growth factor-BB.
    Danikas D; Theodorou SJ; Wurmser E
    Plast Reconstr Surg; 2002 Jun; 109(7):2608-9. PubMed ID: 12045617
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of an ulcerated hemangioma with recombinant platelet-derived growth factor.
    Sugarman JL; Mauro TM; Frieden IJ
    Arch Dermatol; 2002 Mar; 138(3):314-6. PubMed ID: 11902979
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of becaplermin in the closure of pharyngocutaneous fistulas.
    Jakubowicz DM; Smith RV
    Head Neck; 2005 May; 27(5):433-8. PubMed ID: 15776464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperostosis Following Orbital Exenteration.
    Elkhamary SM; Galindo-Ferreiro A; Akaishi P; Muiños-Diaz Y; Cechetti SP; Cintra MB; Cruz AAV
    Ophthalmic Plast Reconstr Surg; 2017; 33(4):241-243. PubMed ID: 27254545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of scleroderma skin ulcers using becaplermin gel and hydrocolloid membrane.
    Yoon J; Giacopelli J; Granoff D; Kobayashi W
    J Am Podiatr Med Assoc; 2002 Jun; 92(6):350-4. PubMed ID: 12070235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced wound healing using topical recombinant human platelet-derived growth factor.
    Seaman S
    Nurse Pract; 2000 Oct; 25(10):85-9. PubMed ID: 11068780
    [No Abstract]   [Full Text] [Related]  

  • 19. Response of ulcerated perineal hemangiomas of infancy to becaplermin gel, a recombinant human platelet-derived growth factor.
    Metz BJ; Rubenstein MC; Levy ML; Metry DW
    Arch Dermatol; 2004 Jul; 140(7):867-70. PubMed ID: 15262700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of becaplermin in progressive limb-threatening pyoderma gangrenosum.
    Freedman BM; Oplinger EH
    Adv Skin Wound Care; 2002; 15(4):180-2. PubMed ID: 12151984
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.